Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celsion Looking At Sale Of BPH Business, Will Shift Focus To Cancer Unit

This article was originally published in The Gray Sheet

Executive Summary

Celsion is planning to submit a PMA for its Adaptive Phased Array (APA) breast cancer treatment by late 2003, while the company also considers the sale of its benign prostatic hypertrophy business

You may also be interested in...



Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy

Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology

Boston Scientific Microwave BPH Pact Follows Tech Investment Strategy

Boston Scientific's equity investment in microwave benign prostatic hyperplasia (BPH) therapy developer Celsion, including worldwide distribution rights, could lead to an outright purchase of the technology

ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI

ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December

Related Content

UsernamePublicRestriction

Register

MT016711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel